PDF(884 KB)
Cost‑effectiveness of atezolizumab as adjuvant therapy following resection for early‑stage， PD‑L1‑high， EGFR/ALK‑negative NSCLC
ZHANG Liang, ZHOU Qiuyun, WANG Jie, HOU Wenjie
Chinese Journal of Hospital Pharmacy ›› 2026, Vol. 46 ›› Issue (7) : 773-778.
PDF(884 KB)
PDF(884 KB)
Cost‑effectiveness of atezolizumab as adjuvant therapy following resection for early‑stage， PD‑L1‑high， EGFR/ALK‑negative NSCLC
({{custom_author.role_en}}), {{javascript:window.custom_author_en_index++;}}| {{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
| 〈 |
|
〉 |
